Effect of intravenous palonosetron on hypotension induced by spinal anesthesia for cesarean section: A randomized controlled trial
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0305913 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift PLOS ONE, 2024. Verfasst von Min Kyoung Kim und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology and Pain Medicine, College of Medicine, Chung-Ang University, Seoul, South Korea. Hauptthemen laut MEDLINE: Anesthesia, Spinal, Cesarean Section, Palonosetron, Hypotension. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
The aim of this study was to evaluate the impact of intravenous palonosetron compared to ondansetron on hypotension induced by spinal anesthesia in women undergoing cesarean section.
Methods
Fifty-four women scheduled for elective cesarean section were, randomly allocated to ondansetron group (n = 27) or palonosetron group (n = 27). Ten minutes prior to the administration of spinal anesthesia, participants received an intravenous injection of either ondansetron or palonosetron. A prophylactic phenylephrine infusion was initiated immediately following the intrathecal administration of bupivacaine and fentanyl. The infusion rate was titrated to maintain adequate blood pressure until the time of fetal delivery. The primary outcome was total dose of phenylephrine administered. The secondary outcomes were nausea or vomiting, the need for rescue antiemetics, hypotension, bradycardia, and shivering. Complete response rate, defined as the absence of postoperative nausea and vomiting and no need for additional antiemetics, were assessed for up to 24 hours post-surgery.
Results
No significant differences were observed in the total dose of phenylephrine used between the ondansetron and palonosetron groups (387.5 μg [interquartile range, 291.3–507.8 μg versus 428.0 μg [interquartile range, 305.0–507.0 μg], P = 0.42). Complete response rates also showed no significant differences between the groups both within two hours post-spinal anesthesia (88.9% in the ondansetron group versus 100% in the palonosetron group; P = 0.24) and at 24 hours post-surgery (81.5% in the ondansetron group versus 88.8% in the palonosetron group; P = 0.7). In addition, there was no difference in other secondary outcomes.
Conclusion
Prophylactic administration of palonosetron did not demonstrate a superior effect over ondansetron in mitigating hemodynamic changes or reducing phenylephrine requirements in patients undergoing spinal anesthesia with bupivacaine and fentanyl for cesarean section.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Anesthesiology and Pain Medicine, College of Medicine, Chung-Ang University, Seoul, South Korea.
- Department of Anesthesiology and Pain Medicine, Chung-Ang University Gwangmyeong Hospital, Gyeonggi-do, South Korea.
- Department of Anesthesiology and Pain Medicine, Chung-Ang University Hospital, Seoul, South Korea.
ORCID-Profile: Chong Wha Baek
Zitieren
APA
Kim, M. K., Kim, I., Kang, H., Wi, W., Park, Y. H., Jung, Y. H., Woo, Y. C., & Baek, C. W. (2024). Effect of intravenous palonosetron on hypotension induced by spinal anesthesia for cesarean section: A randomized controlled trial. PLOS ONE. https://doi.org/10.1371/journal.pone.0305913
Vancouver
Kim MK, Kim I, Kang H, Wi W, Park YH, Jung YH, et al. Effect of intravenous palonosetron on hypotension induced by spinal anesthesia for cesarean section: A randomized controlled trial. PLOS ONE. 2024. doi:10.1371/journal.pone.0305913
BibTeX
@article{Kim2024,
author = {Kim, Min Kyoung and Kim, Injeong and Kang, Hyun and Wi, Wongook and Park, Yong Hee and Jung, Yong Hun and Woo, Young Cheol and Baek, Chong Wha},
title = {Effect of intravenous palonosetron on hypotension induced by spinal anesthesia for cesarean section: A randomized controlled trial},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0305913}
}
EUVIMED